MARAVAI LIFESCIENCES HOLDINGS (MRVI) Company Report

Maravai LifeSciences reported Q4 2025 revenue of $49.9 million and full-year 2025 revenue of $185.7 million. The company returned to positive Adjusted EBITDA of $0.5 million in Q4 2025, though full-year 2025 Adjusted EBITDA was $(31.2) million.
For Q4 2025, GAAP Net Loss was $63.0 million and Adjusted EPS was $(0.04), while full-year 2025 GAAP Net Loss was $230.8 million and Adjusted EPS was $(0.29).
The company issued 2026 guidance, projecting revenue between $200 million and $210 million and Adjusted EBITDA between $18 million and $20 million.
In Q4 2025, the TriLink segment generated $34.6 million in revenue, with its base business revenue growing 25% year-over-year, and the Cygnus segment reported $15.3 million in revenue, growing 4%.
Maravai LifeSciences announced the completion of its remediation plan and the dismissal of a securities class action.

Feb 25, 2026, 10:00 PM

Presentation

Maravai LifeSciences Reports Q4 and Full-Year 2025 Results, Provides 2026 Guidance

MRVI

Earnings

Guidance Update

Revenue Acceleration/Inflection

Maravai LifeSciences reported Q4 2025 revenue of $49.9 million and full-year 2025 revenue of $185.7 million, exceeding guidance. Excluding a $14.3 million comparison from high-volume CleanCap sales in Q4 2024, Q4 revenue grew 18%.
The company achieved positive adjusted EBITDA of $536 thousand in Q4 2025, its first positive quarter in four, driven by exceeding $50 million in cost-saving targets. Full-year 2025 adjusted EBITDA was negative $31.2 million.
For 2026, Maravai expects total revenue of $200 million-$210 million, representing 8%-13% growth, and adjusted EBITDA of $18 million-$20 million, an improvement of $50 million-$52 million over 2025.
Key operational improvements include TriLink's base revenue growth of 25% (excluding COVID CleanCap comp) and Cygnus's 4% revenue growth in Q4 2025, alongside a voluntary $50 million debt repayment in Q1 2026. The company also announced the dismissal of securities class action lawsuits.

Feb 25, 2026, 10:00 PM

Transcript

Maravai LifeSciences Reports Q4 and Full-Year 2025 Results, Provides 2026 Guidance

MRVI

Earnings

Guidance Update

Legal Proceedings

Maravai LifeSciences reported Q4 2025 revenue of $49.9 million and full-year 2025 revenue of $185.7 million, with Q4 revenue growing 18% year-over-year excluding high-volume COVID CleanCap sales.
The company achieved positive adjusted EBITDA of $536 thousand in Q4 2025, marking its first return to positive adjusted EBITDA in four quarters, driven by exceeding $65 million in annualized cost-saving targets.
For 2026, Maravai expects total revenue of $200 million-$210 million and adjusted EBITDA of $18 million-$20 million, alongside a projected 1,200 basis point gross margin expansion.
Operational highlights include segment renaming to TriLink and Cygnus, a $50 million voluntary debt repayment in Q1 2026, and the dismissal of securities class action lawsuits.

Feb 25, 2026, 10:00 PM

Transcript

Maravai LifeSciences Reports Q4 2025 Results and Provides 2026 Guidance

MRVI

Earnings

Guidance Update

Revenue Acceleration/Inflection

Maravai LifeSciences (MRVI) reported Q4 2025 revenue of $49.9 million and achieved positive adjusted EBITDA of $536 thousand, marking its first return to positive adjusted EBITDA in four quarters.
The company exceeded its cost-saving targets, now estimating annualized savings of greater than $65 million, and expects full-year 2026 adjusted EBITDA of $18 million to $20 million.
For 2026, Maravai LifeSciences forecasts total revenue between $200 million and $210 million, with an anticipated gross margin expansion of approximately 1,200 basis points year-over-year.
The company's segments were renamed to TriLink and Cygnus, and a voluntary $50 million debt repayment was made in Q1 2026.

Feb 25, 2026, 10:00 PM

Transcript

Maravai LifeSciences Reports Q4 and Full Year 2025 Financial Results and Issues 2026 Guidance

MRVI

Earnings

Guidance Update

Demand Weakening

Maravai LifeSciences reported Q4 2025 revenue of $49.9 million and Adjusted EBITDA of $0.5 million, exceeding revenue expectations and returning to positive Adjusted EBITDA for the quarter.
For the full year 2025, the company recorded revenue of $185.7 million and an Adjusted EBITDA of $(31.2) million.
The company provided full year 2026 revenue guidance in the range of $200 million to $210 million and Adjusted EBITDA guidance between $18 million and $20 million.
The TriLink segment's revenue decreased by 17.4% in Q4 2025 and 39.0% for the full year 2025, primarily due to a lack of high-volume CleanCap orders for commercial phase vaccine programs, while the Cygnus segment's revenue increased by 4.1% in Q4 2025 and 5.0% for the full year 2025.

Feb 25, 2026, 9:05 PM

8-K

Maravai LifeSciences Reports Q4 and Full Year 2025 Financial Results

MRVI

Earnings

Guidance Update

Demand Weakening

Maravai LifeSciences reported Q4 2025 revenue of $49.9 million and a net loss of $(63.0) million, with Adjusted EBITDA of $0.5 million, marking a return to positive Adjusted EBITDA for the quarter.
For the full year 2025, the company recorded revenue of $185.7 million, a net loss of $(230.8) million, and Adjusted EBITDA of $(31.2) million.
The company introduced full year 2026 guidance, expecting revenue between $200 million and $210 million and Adjusted EBITDA between $18 million and $20 million.
Segment revenue for Q4 2025 showed TriLink revenue decreased by 17.4% to $34.6 million primarily due to a lack of high-volume CleanCap orders, while Cygnus revenue increased by 4.1% to $15.3 million.

Feb 25, 2026, 9:01 PM

Press Release

Maravai Discusses Strategic Actions, Q4 Outlook, and 2026 Growth Drivers

MRVI

Management Change

Guidance Update

New Projects/Investments

Maravai's new management team has implemented significant restructuring, removing over $50 million in annualized expenses through reduced headcount, facility rationalization, and CapEx reduction, aiming to return the business to revenue growth, positive EBITDA, and cash flow generation in 2026.
The company reinstated guidance for the year, implying a $49 million Q4, a sequential step up driven by CDMO orders and GMP variability, and has improved visibility into its order book for the balance of the year and into 2026.
Maravai introduced ModTail technology, which enhances mRNA protein expression durability and protection against degradation, opening new customer segments, and continues to refine IVT kits and leverage its mRNA builder e-commerce platform.
The BST business grew 7% in Q3 and mid-single digits year-to-date, driven by MockViral kits and mass spec analytical services, with expectations for acceleration to high single-digit growth with further innovation.
The company anticipates $10 million-$20 million per year in vaccine-related CleanCap revenue for 2026 and beyond, which will be integrated into the overall GMP business guidance.

Nov 19, 2025, 10:00 AM

Transcript

Maravai Discusses Restructuring, 2026 Outlook, and Product Strategy at Jefferies Conference

MRVI

Management Change

Guidance Update

Revenue Acceleration/Inflection

Maravai's new management team has implemented a restructuring plan, targeting over $50 million in annualized expense reductions through reduced headcount, facility rationalization, and CapEx cuts, aiming for a leaner organization and financial discipline.
The company reinstated guidance, projecting a significant step up in Q4 due to CDMO orders and GMP variability, and is focused on returning to revenue growth and positive EBITDA and cash flow generation in 2026.
Maravai anticipates $10 million-$20 million per year from vaccine-related CleanCap in 2026 and beyond, which will be integrated into the overall GMP business.
Strategic product development emphasizes fewer, more impactful innovations like ModTail technology and IVT kits, while the commercial team focuses on larger orders (over $25,000) that represent 60% of revenue.
The BST business grew 7% in Q3, driven by MockViral kits and analytical services, with MockViral having the potential to reach tens of millions of dollars.

Nov 19, 2025, 10:00 AM

Transcript

Maravai CFO Discusses Restructuring, 2026 Outlook, and Q4 2025 Guidance

MRVI

Guidance Update

Layoffs

Revenue Acceleration/Inflection

Maravai has undertaken significant restructuring efforts, resulting in over $50 million in annualized expense reductions through measures like a 25% headcount reduction, facility rationalization, and CapEx cuts.
The company aims to return to revenue growth and positive EBITDA and cash flow generation in 2026, with a specific target of achieving adjusted EBITDA profitability in the back half of 2026.
Guidance for Q4 2025 implies approximately $49 million in revenue, representing a sequential step-up driven by CDMO orders and GMP variability.
Maravai anticipates $10 million-$20 million annually in vaccine-related CleanCap revenue for 2026 and beyond, which will be integrated into the overall GMP business.
The company's commercial strategy includes focusing sales efforts on larger orders (over $25,000, representing 60% of revenue) and leveraging new products like ModTail technology to expand customer reach.

Nov 19, 2025, 10:00 AM

Transcript

Maravai LifeSciences Details Strategic Review Progress and 2026 Outlook

MRVI

Guidance Update

Demand Weakening

New Projects/Investments

Maravai LifeSciences Holdings Inc. (MRVI) has undergone a strategic review and restructuring, committing to over $50 million in annualized expense savings, with $3 million realized in Q3 2025 and an additional $7 million+ expected in Q4 2025.
The company has improved its forecasting capabilities and reorganized sales teams to focus on higher-revenue orders, aiming to enhance revenue visibility and efficiency.
Despite Nucleic Acid Purification (NAP) revenues being down 20% to $25 million in Q3 2025, Maravai anticipates a step back up with strong double-digit growth in Q4 2025 and expects growth in the NAP segment in 2026.
Maravai projects $10 million to $20 million in COVID-related revenue for 2026, a significant increase from zero in 2025, following $66 million in 2024.
The company expects to achieve positive EBITDA for the full year 2025, driven by cost benefits and expense reductions, which are anticipated to make the business profitable even at lower revenue levels.

Nov 12, 2025, 3:00 PM

Transcript

Earnings Transcripts

Quarterly earnings call transcripts for MARAVAI LIFESCIENCES HOLDINGS.

Q4 2025

Feb 25, 2026

→

Q3 2025

Nov 6, 2025

→

Q2 2025

Aug 11, 2025

→

View All Transcripts

Ask Fintool AI Agent

Get instant answers from SEC filings, earnings calls & more

What did Bernd Brust say about margins?What are MARAVAI LIFESCIENCES HOLDINGS's strategic priorities?How is MARAVAI LIFESCIENCES HOLDINGS positioned vs competitors?How did MARAVAI LIFESCIENCES HOLDINGS do last quarter?

MARAVAI LIFESCIENCES HOLDINGS (MRVI)

Analyst Earnings Quarterly Reports

Q3 2025

Q2 2025

Q1 2025

Q4 2024

Executives

Bernd Brust

Christine Dolan

Kurt Oreshack

Peter Leddy

Rajesh Asarpota

Rebecca Buzzeo

Board Members

Constantine Mihas

Gregory T. Lucier

John DeFord

Luke Marker

R. Andrew Eckert

Sean Cunningham

Susannah Gray

Analyst Coverage

Justin Bowers

Subbu Nambi

Brandon Couillard

Daniel Arias

Matthew Hewitt

Matthew Parisi

Matthew Stanton

Matt Larew

Catherine Schulte

Daniel Leonard

Doug Schenkel

Josh Heinen

Matt Stanton

Tejas Savant

Anders Nowokowski

Conor Noel McNamara

Dan Arias

Douglas Schenkel

Kyle Crews

Madeline Mollman

Matt Hewett

Matt Hewitt

Matthew Larew

Matt Sykes

Yuko Oku

Latest news

Earnings Transcripts

Q4 2025

Q3 2025

Q2 2025

Ask Fintool AI Agent